Literature DB >> 33477685

Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction.

Mar Álvarez1, Enrique Sapena-Ventura1, Joanna Luczkowiak1, Samara Martín-Alonso1, Luis Menéndez-Arias1.   

Abstract

HIV reverse transcriptases (RTs) convert viral genomic RNA into double-stranded DNA. During reverse transcription, polypurine tracts (PPTs) resilient to RNase H cleavage are used as primers for plus-strand DNA synthesis. Nonnucleoside RT inhibitors (NNRTIs) can interfere with the initiation of plus-strand DNA synthesis by enhancing PPT removal, while HIV RT connection subdomain mutations N348I and N348I/T369I mitigate this effect by altering RNase H cleavage specificity. Now, we demonstrate that among approved nonnucleoside RT inhibitors (NNRTIs), nevirapine and doravirine show the largest effects. The combination N348I/T369I in HIV-1BH10 RT has a dominant effect on the RNase H cleavage specificity at the PPT/U3 site. Biochemical studies showed that wild-type HIV-1 and HIV-2 RTs were able to process efficiently and accurately all tested HIV PPT sequences. However, the cleavage accuracy at the PPT/U3 junction shown by the HIV-2EHO RT was further improved after substituting the sequence YQEPFKNLKT of HIV-1BH10 RT (positions 342-351) for the equivalent residues of the HIV-2 enzyme (HQGDKILKV). Our results highlight the role of β-sheets 17 and 18 and their connecting loop (residues 342-350) in the connection subdomain of the large subunit, in determining the RNase H cleavage window of HIV RTs.

Entities:  

Keywords:  DNA synthesis; HIV; RNase H; antiretroviral drug resistance; doravirine; reverse transcriptase

Year:  2021        PMID: 33477685      PMCID: PMC7831940          DOI: 10.3390/v13010131

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  58 in total

1.  HIV-1 genome nuclear import is mediated by a central DNA flap.

Authors:  V Zennou; C Petit; D Guetard; U Nerhbass; L Montagnier; P Charneau
Journal:  Cell       Date:  2000-04-14       Impact factor: 41.582

2.  Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).

Authors:  Julie Q Hang; Yu Li; Yanli Yang; Nick Cammack; Tara Mirzadegan; Klaus Klumpp
Journal:  Biochem Biophys Res Commun       Date:  2006-11-14       Impact factor: 3.575

Review 3.  HIV-1 reverse transcription.

Authors:  Wei-Shau Hu; Stephen H Hughes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

4.  A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Galina N Nikolenko; Krista A Delviks-Frankenberry; Vinay K Pathak
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

Review 5.  Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.

Authors:  Francesc Xavier Ruiz; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2020-01-11       Impact factor: 6.809

6.  Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization.

Authors:  Mary Jane McWilliams; John G Julias; Stefan G Sarafianos; W Gregory Alvord; Eddy Arnold; Stephen H Hughes
Journal:  Virology       Date:  2006-02-10       Impact factor: 3.616

7.  Rational Design of Doravirine: From Bench to Patients.

Authors:  Carey Hwang; Ming-Tain Lai; Daria Hazuda
Journal:  ACS Infect Dis       Date:  2019-12-19       Impact factor: 5.084

8.  Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.

Authors:  Gilberto Betancor; Mar Álvarez; Barbara Marcelli; Cristina Andrés; Miguel A Martínez; Luis Menéndez-Arias
Journal:  Nucleic Acids Res       Date:  2015-02-06       Impact factor: 16.971

9.  N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Authors:  Soo-Huey Yap; Chih-Wei Sheen; Jonathan Fahey; Mark Zanin; David Tyssen; Viviane Dias Lima; Brian Wynhoven; Michael Kuiper; Nicolas Sluis-Cremer; P Richard Harrigan; Gilda Tachedjian
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

10.  Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.

Authors:  Maryam Ehteshami; Greg L Beilhartz; Brian J Scarth; Egor P Tchesnokov; Suzanne McCormick; Brian Wynhoven; P Richard Harrigan; Matthias Götte
Journal:  J Biol Chem       Date:  2008-06-10       Impact factor: 5.157

View more
  1 in total

1.  Stephen Oroszlan and Retroviral Proteins.

Authors:  Alan Rein
Journal:  Viruses       Date:  2022-01-29       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.